New guidance on contraceptive methods and frequency of pregnancy testing to reduce inadvertent exposures during pregnancy in a woman taking a medicine of teratogenic potential has been published by the MHRA in consultation with advisory committees the Commission on Human Medicines and Medicines for Women’s Health Expert Advisory Group.
Further details of the guidance is available on the MHRA website